Parvovirus infection after renal transplant.

The Lancet (Impact Factor: 39.21). 12/1986; 2(8517):1226-7. DOI: 10.1016/S0140-6736(86)92245-2
Source: PubMed
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Since its discovery, human parvovirus B19 has been linked with a broad spectrum of clinical syndromes. An aetiological role for the virus has been confirmed in erythema infectiosum, transient aplastic crisis, persistent infection manifesting as pure red cell aplasia in immunocompromised persons, non-immune hydrops fetalis and arthritis. Less commonly recognised, but receiving increasing attention recently, are the neurological manifestations, a variety of which have been described in patients with either clinically diagnosed or laboratory confirmed B19 infection. The purpose of this review is to summarise present knowledge of B19, its known and potential pathogenic mechanisms and its association with human diseases, particularly those with neurological manifestations. The outcome of the review supports an aetiological role of the virus in neurological disease. However, the pathogenesis remains unknown and elucidating this is a priority. INTRODUCTION Human parvovirus B19 (B19), the first known par-vovirus to infect humans, was discovered during evaluation of serum hepatitis B surface antigen tests using a panel of sera [1]. The first association between B19 infection and a clinical syndrome was with hypoplastic crisis in children with sickle-cell anaemia [2]. Two years later, development of a new serological method for detecting specific anti-B19 IgM antibodies proved the causative role of the virus in erythema infectiosum, a com-mon childhood disease [3]. B19 has also been shown to cause persistent infection manifesting as pure red cell aplasia in immunocompromised persons [4], non-immune hydrops fetalis [5,6] and arthritis [7,8]. In subsequent years, studies of B19 in humans determined the aetiological rela-tionship of B19 infection with a broad spectrum of diseases. Recent improvements regarding the development of immunological and molecular techniques provided new insight into the virology, pathogenesis and various clinical manifestation of B19 infection.
  • Current Opinion in Organ Transplantation 01/2003; 8(4):283-287. DOI:10.1097/00075200-200312000-00005 · 2.38 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Described for the first time in 1986, Parvovirus B19 (B19V) infection in kidney transplant recipients remains little-known and probably underestimated. The aims of this study were to establish B19V infection frequency during the first year after kidney transplant and to determine predisposing factors and manifestations of the infection in renal transplant recipients. Sixty consecutive adult patients, transplanted less than a year before, were included in this study. B19V and other opportunistic viral infections were detected retrospectively in plasma samples collected every 15 days during the first 3 months and every month from 3 months to 1 year following the kidney transplant. Demographic characteristics, immunosuppressive treatment and biological findings were recorded on each sampling date. Six patients (10%) presented B19V viremia, while eight CMV (13.3%), seven EBV (11.7%), five HHV-6 (8.3%), five BKV (8.3%), and two adenovirus (3.3%) infections were detected. The mean value of B19V viral load was 149 UI/ml. B19V infections were either reactivation or reinfection due to genotype two in five cases, while one case of primary infection with genotype 1 was observed. Neither risk factors nor biological consequences of B19V infection have been identified. These results rank B19V third among opportunistic viral infections occurring during the first year after a kidney transplant. With regard to this high incidence, and even if the risk factors and biological consequences of the infection should be assessed in larger studies, the question of systematic screening and follow-up of B19V infection in kidney transplant recipients is relevant. J. Med. Virol. 85: 1115-1121, 2013. © 2013 Wiley Periodicals, Inc.
    Journal of Medical Virology 06/2013; 85(6):1115-21. DOI:10.1002/jmv.23557 · 2.22 Impact Factor